H1B Salary Data

Home › Employers › SAI-Med Partners LLC

SAI-Med Partners LLC: H-1B salaries and sponsorship

SAI-Med Partners LLC filed 16 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 16. Median offered salary: $110,000.

Applications (LCAs)16
Certified16
Employer addressReading, PA
H-1B dependent employerNo
Median offered salary$110,000
Middle half of salaries$86,500–$137,500
10th–90th percentile$85,000–$169,000

Does SAI-Med Partners LLC sponsor H-1B visas?

SAI-Med Partners LLC filed 16 labor condition applications in fiscal years 2023–2026, the latest submitted on Jun 11, 2026. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.

Salaries by job title

Job titleLCAsMedian salary
Life Sciences Markets Consultant/Project Manager5$100,000
Life Sciences Markets Consultant3$85,000
Assoc Director - Specialty Therapeutics and Related (STAR)1$110,000
Senior Director, Oncology Practice1$145,000
Director - Specialty Therapeutics and Related (STAR)1$130,000
TheraTraQ Pharma/Healthcare Services Division Head1$200,000
Associate Director, Immunology Practice1—
Vice President, Oncology Practice1$185,000
Exec Director - Specialty Therapeutics and Related (STAR)1$145,000
Associate Director - Generics, Biosimilars and Mature Brands1$120,000

Applications by fiscal year

Fiscal yearLCAsMedian salary
FY20236$97,500
FY20243$150,000
FY20253$100,000
FY20264$132,500

Prevailing wage levels

The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.

Where the jobs are

Occupations

Latest applications

Job titleBase salaryLocationSubmittedStart dateStatus
Associate Director - Generics, Biosimilars and Mature Brands$120,000–$150,000
Level IV
Reading, PAJun 11, 2026Jun 22, 2026Certified
Life Sciences Markets Consultant$85,000–$115,000
Level II
Reading, PAJun 1, 2026Jun 8, 2026Certified
Exec Director - Specialty Therapeutics and Related (STAR)$145,000–$230,000
Level II
Reading, PAApr 9, 2026May 15, 2026Certified
Vice President, Oncology Practice$185,000–$260,000
Level III
Reading, PAApr 7, 2026May 4, 2026Certified
Life Sciences Markets Consultant/Project Manager$88,000–$138,000
Level III
Reading, PAJun 17, 2025Jun 24, 2025Certified
Life Sciences Markets Consultant/Project Manager$115,000–$150,000
Level III
Reading, PAMar 25, 2025Apr 7, 2025Certified
Life Sciences Markets Consultant/Project Manager$100,000–$140,000
Level III
Reading, PADec 19, 2024May 1, 2025Certified
Associate Director, Immunology Practice$135,200–$156,000
part-time · Level II
Reading, PAJun 18, 2024Jul 1, 2024Certified
Life Sciences Markets Consultant/Project Manager$100,000–$135,000
Level III
Reading, PAMar 12, 2024Apr 1, 2024Certified
TheraTraQ Pharma/Healthcare Services Division Head$200,000–$400,000
Level IV
Reading, PAMar 4, 2024May 1, 2024Certified
Life Sciences Markets Consultant/Project Manager$80,000–$120,000
Level III
Reading, PASep 13, 2023Oct 3, 2023Certified
Senior Director, Oncology Practice$145,000–$215,000
Level III
Reading, PAAug 8, 2023Aug 18, 2023Certified
Director - Specialty Therapeutics and Related (STAR)$130,000–$170,000
Level I
Reading, PAJul 17, 2023Aug 1, 2023Certified
Assoc Director - Specialty Therapeutics and Related (STAR)$110,000–$160,000
Level IV
Reading, PAJun 12, 2023Jul 1, 2023Certified
Life Sciences Markets Consultant$85,000–$110,000
Level II
Los Angeles, CAJun 12, 2023Jun 24, 2023Certified
Life Sciences Markets Consultant$85,000–$110,000
Level II
Reading, PAApr 11, 2023Apr 24, 2023Certified

Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).